Patients Sponsored Case Study: MHRA and AstraZeneca Agile, responsive regulation helps early breast cancer patients to benefit from a study to potentially improve survival outcomes.
Market Access FDA approval numbers soar after COVID troubles The FDA released its overview of 2023 and the drugs it had approved during the year.
News EU approves AZ's Imfinzi plus chemo for advanced biliary tra... AstraZeneca’s (AZ) Imfinzi (durvalumab) has been approved in the
News Otsuka eyes early filing of IgAN drug after phase 3 readout Otsuka is hoping to file for approval of its anti-APRIL antibody sibeprenlimab as a treatment for kidney disorder IgA nephropathy (IgAN) after the drug hit the target in a phase 3 trial.
Sales & Marketing Sponsored Global reach, personal touch: Mastering customer engagement ... In today's interconnected pharma market, the ability to scale engagement across borders is essential for survival and growth.